XML 44 R35.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue $ 6,897       $ 6,897   $ 15,857
Drug product revenue recognized 29,806   $ 24,364   90,633 $ 62,793  
Royalty Revenue [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue 100       100    
Drug Product Revenue [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized 1,093   8,648   8,687 (168)  
Drug Product Revenue [Member] | Europe [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized 1,076   0   1,076 0  
Drug Product Revenue [Member] | Japan [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized   $ 9,800          
Drug Product Revenue [Member] | Japan [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized 17   (1,974)   7,611 $ 2,056  
Drug Product Revenue [Member] | API Shipment [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized   (2,200) $ (2,000) $ 4,000      
Bulk Drug Product [Member] | Astellas Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         43,300    
Bulk Drug Product [Member] | Astra Zeneca Agreements [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Drug product revenue recognized         11,200    
Bulk Drug Product [Member] | E U Supply And Astellas Agreement [Member] | Europe [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Deferred Revenue 23,200       $ 23,200    
Billed Contracts Receivable   $ 49,200          
Burdened manufacturing costs $ 1,000